Daxas REMS May Be Key To Approval After "Complete Response" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seems more likely to approve the COPD if labeling is restricted to moderate-to-severe patients with chronic bronchitis, but Forest will probably need to show that it can limit use.
You may also be interested in...
For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms
On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.
For Forest, Two Launches And Two Filings Planned In 2011 As Patent Cliff Looms
On the heels of a strong quarter, Forest has launched the antibiotic Teflaro and plans to introduce the oral COPD candidate Daxas, later this year pending FDA approval.
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.